GlobeNewswire by notified

Information on the total number of voting rights and shares

Share

Ghent, Belgium, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Press release - regulated information

Biotalys NV (hereafter the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions (Euronext - BTLS), today announces that 10,000 new shares were issued on 18 January 2023 as a result of the exercise of subscription rights under the Company’s long term incentive plan.

In view hereof, and in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings (the “Belgian Act”), the outstanding share capital and outstanding voting securities of the Company can be summarised as follows:

  • Share capital: EUR 44,564,320.02
  • Total number of securities carrying voting rights: 30,959,454 (all ordinary shares)
  • Total number of voting rights (= denominator): 30,959,454 (all relating to ordinary shares)
  • Number of rights to subscribe for securities carrying voting rights not yet issued:
    • 2,162,109 “ESOP Warrants”, entitling their holders to subscribe for a total number of 2,162,109 profit certificates which will, if and when issued, automatically convert into a total number of maximum 1,081,052 securities carrying voting rights (all ordinary shares)
    • 700,252 “ESOP IV Warrants”, entitling their holders to subscribe for a total number of maximum 700,252 securities carrying voting rights (all ordinary shares). Under ESOP IV an additional number of 1,021,407 ESOP IV Warrants are still available for future grants.
    • 6,500 share units, awarded in aggregate to the independent directors of the Company in the framework of its remuneration policy. Each share unit contains the obligation – subject to vesting of all share units – to subscribe to one new share of the Company at an issue price of one EUR per share-unit. Cash settlement is possible. The conditions of the share units are described in the remuneration policy of the Company.
  • The Company has no outstanding convertible bonds or non-voting shares.

Pursuant to the Belgian Act, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.
For further information, please contact:
Toon Musschoot, Head Investor Relations & Communication
T: +32 (0)9 274 54 00
E: Toon.Musschoot@biotalys.com

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company protecting crops and food with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Interoil's Annual Statement of Reserves 2023 released23.4.2024 21:35:25 CEST | Press release

Oslo, 23 April 2024 Interoil Exploration and Production ASA today released the Annual Statement of Reserves for 2023. Please find the document attached. The report is also available on the company website. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act and is prepared in accordance with Oslo Stock Exchange's Listing and disclosure requirements for oil and natural gas companies. + + + Please direct any question to ir@interoil.no Interoil Exploration and Production ASA is a Norwegian based exploration and production company - listed on the Oslo Stock Exchange - with focus on Latin America. The Company is operator and license holder of several production and exploration assets in Colombia and Argentina. Interoil currently employs approximately 50 people and is headquartered in Oslo. Attachment Interoil reserves statement 2023

Nokia Corporation: Repurchase of own shares on 23.04.202423.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 23 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 23.04.2024 Espoo, Finland – On 23 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6153.40CEUX--BATE--AQEU--TQEX--Total385,6153.40 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors23.4.2024 19:42:34 CEST | Press release

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and appro

Grant of warrants23.4.2024 19:20:21 CEST | Press release

23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o

TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse23.4.2024 19:10:28 CEST | pressemeddelelse

Virksomheden er ene om at tilbyde en global løsning, der omfatter e-fakturering, CTC-løsninger og et omfattende EDI-netværk, alt sammen problemfritintegreret med B2B e-handels- og ERP-systemer KØBENHAVN, Danmark, April 23, 2024 (GLOBE NEWSWIRE) -- TrueCommerce, en global leverandør af forsyningskæde- og handelspartnerforbindelser, integration og løsninger via flere kanaler, har i dag givet meddelelse om sin globale løsning til e-fakturering og Continuous Transaction Controls (CTC), der gør det muligt for organisationer at holde trit med de konstant skiftende juridiske krav overalt i verden og understøtter elektronisk fakturering, som opfylder de gældende krav. TrueCommerce er en global markedsaktør, der understøtter både e-fakturering og CTC og giver adgang til et omfattende globalt EDI-netværk samt B2B e-handel og ERP-integration. På grund af kompleksiteten i at navigere i et landskab af stadigt skiftende landespecifikke e-faktureringskrav og deadlines, står virksomheder over for en s

HiddenA line styled icon from Orion Icon Library.Eye